JURL-MK1 (c-kit(high)/CD30-/CD40-) and JURL-MK2 (c-kit(low)/CD30+/CD40+) cell lines: 'two-sided' model for investigating leukemic megakaryocytopoiesis.
Two novel cell lines (JURL-MK1 and JURL-MK2) have been established from the peripheral blood of a patient in the blastic phase of chronic myelogenous leukemia. The cells grow in a single cell suspension with doubling times of 48 h (JURL-MK1) and 72 h (JURL-MK2). Cytogenetic analysis has shown that JURL-MK1 is hypodiploid whereas JURL-MK2 is near triploid and that both cell lines retain t(9;22). Moreover, JURL-MK1 and JURL-MK2 have a bcr/abl-fused gene with the same junction found in the patient's fresh cells, and both cell lines express the b3/a2 type of hybrid bcr/abl mRNA. The morphology and immunophenotype of these cell lines are reminiscent of megakaryoblasts. In both lines, a limited but consistent percentage of cells expresses gpIIbIIIa (CD41a), gpIIIa (CD61) and CD36, with no expression of gplb (CD42b), glycophorin A, hemoglobin and CD34. Both cell lines are clearly positive for CD33, CD43, CD45RO and CD63, while CD13, CD44, CD54, CD30 and CD40 are specific features of JURL-MK2. Among cytokine receptors, CD117/SCF-R is strongly displayed by a large fraction of JURL-MK1 cells but is hardly detectable on about 20% JURL-MK2 cells. Both cell lines are clearly positive for CD25/IL2R alpha, while a marked expression of CD116/GM-CSF-R and CDw123/IL3R alpha is restricted to JURL-MK2. Induction of cell differentiation in vitro has demonstrated that TPA is able to modulate the JURL-MK1 phenotype, causing an increased expression of platelet-associated antigens. The JURL-MK2 phenotype is easily modulated by both TPA and DMSO, which cause an increased expression of CD41a and CD117 accompanied by a decreased expression of CD30. Proliferation studies demonstrated that JURL-MK1 cell growth is enhanced by stem cell factor, while JURL-MK2 proliferation is unaffected by this cytokine. JURL-MK1 and JURL-MK2 are two novel cell lines with divergent biological features, representing a 'two-sided' model for investigating new aspects of megakaryocytopoiesis.
Di Noto
R
R
Divisione di Oncologia Sperimentale C, Istituto Nazionale dei Tumori, Naples, Italy.
Luciano
L
L
Lo Pardo
C
C
Ferrara
F
F
Frigeri
F
F
Mercuro
O
O
Lombardi
M L
ML
Pane
F
F
Vacca
C
C
Manzo
C
C
Salvatore
F
F
Rotoli
B
B
Del Vecchio
L
L
D000954:Antigens, Surface / Q000032:analysis; D019013:CD40 Antigens / Q000032:analysis; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D002871:Chromosome Banding; D004279:DNA, Viral / Q000032:analysis; D004121:Dimethyl Sulfoxide / Q000494:pharmacology; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006410:Hematopoiesis; D004854:Herpesvirus 4, Human / Q000235:genetics; D006801:Humans; D016130:Immunophenotyping; D017403:In Situ Hybridization; D007621:Karyotyping; D017730:Ki-1 Antigen / Q000032:analysis; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D008297:Male; D008533:Megakaryocytes; D008875:Middle Aged; D019009:Proto-Oncogene Proteins c-kit / Q000032:analysis; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014178:Translocation, Genetic
D000954:Antigens, Surface; D019013:CD40 Antigens; D004279:DNA, Viral; D017730:Ki-1 Antigen; D019009:Proto-Oncogene Proteins c-kit; D016044:Fusion Proteins, bcr-abl; D013755:Tetradecanoylphorbol Acetate; D004121:Dimethyl Sulfoxide